Oral Esketamine Maintenance Treatment for Treatment-Resistant Depression: Clinical Outcomes During an Off-Label Treatment Program.
Sanne Y Smith-Apeldoorn, Jolien K E Veraart, Jan Spijker, Annemarie van der Meij, Jeanine Kamphuis, Robert A Schoevers
Depression and Anxiety 2026 DOI: 10.1155/da/8320239 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational study Peer reviewed |
|---|---|
| Sample size | 221 |
| Population | Patients with severe treatment-resistant unipolar depression |
| Intervention | Esketamine |
| Dose | max 3.0 mg/kg twice a week |
| Duration | 6-week induction followed by maintenance with mean exposure 20.8 months |
| Measures | 17-item Hamilton Depression Rating Scale (HDRS17) |
| Topics | Depression Esketamine Ketamine |
| Key findings | Over a mean 20.8 months of at-home oral esketamine maintenance, HDRS17 depression severity showed no significant change from maintenance baseline (mean difference 0.825, 95% CI -0.759 to 2.410). Among initial responders, 23.1% sustained response, and 60.0% of those meeting minimal clinically important difference criteria sustained that improvement. The authors suggest possible symptom stability but note causal inferences cannot be drawn; 12.9% discontinued partly due to adverse events. |
Abstract
Ketamine and esketamine maintenance treatment show promise in maintaining initial antidepressant effects, yet further research is needed to optimize long-term outcomes. This observational study aimed to assess long-term depression symptom severity, safety, and tolerability in a cohort of patients receiving at-home oral esketamine maintenance treatment. Between June 2017 and March 2024, 221 patients with severe treatment-resistant unipolar depression were enrolled directly or trial-transferred into an off-label induction treatment program. After 6 weeks of individually titrated oral esketamine (twice a week, max 3.0 mg/kg) administered in the clinic, 93 patients continued to maintenance treatment at home (max 3.0 mg/kg twice a week). Our primary outcome was change in depression symptom severity during maintenance treatment, measured by the 17-item Hamilton Depression Rating Scale (HDRS17). Mean exposure to esketamine in the maintenance phase was 20.8 months. We found no difference between the HDRS17 total score at the maintenance baseline and last-observation-carried-forward (mean difference = 0.825, 95% CI = -0.759 to 2.410, p = 0.302). Of the 26 initial responders (≥50% decrease in HDRS17 at the end of induction treatment), 23.1% met sustained response criteria throughout maintenance treatment. Of the 40 patients meeting minimal clinically important difference (MCID) criteria (≥27.1% decrease in HDRS17 at the end of induction treatment), 60.0% met sustained MCID criteria throughout maintenance treatment. Eleven patients (11.8%) successfully tapered off esketamine maintenance treatment. Twelve patients (12.9%) discontinued maintenance treatment (partly) due to adverse events. These findings suggest that oral esketamine maintenance home treatment may be associated with sustained symptom stability in patients with severe treatment-resistant depression (TRD), although causal inferences cannot be drawn from this observational study. Although some potential long-term side effects require monitoring and further examination, overall, treatment was safe and well-tolerated.
Comparable studies
Other observational and cohort studies on esketamine for depression, most cited first.
Citations in the library
Cites 37
- Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression JAMA Psychiatry June 5, 2019
- Ketamine use: a review Addiction July 21, 2011
- Side-effects associated with ketamine use in depression: a systematic review. The Lancet Psychiatry 2018
- Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial. American Journal of Psychiatry March 29, 2019
- Blinding and expectancy confounds in psychedelic randomized controlled trials Expert Review of Clinical Pharmacology May 26, 2021
and 32 more in the library